BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that Stephen M. Simes, president and chief executive officer, will participate in a panel discussion at the 8th annual BIO CEO & Investor Conference. Mr. Simes will serve as a panelist at the "What is New in Sexual/Gender Health?" Reproductive Focus Session, to be held Tuesday, February 14 at 4:00 p.m. ET at the Waldorf-Astoria Hotel in New York City. The panel will discuss new research developments in reproductive health for men and women, and how pharmaceutical and biotech companies approach this market. To listen to the audio webcast, visit http://ceo.bio.org/opencms/ceo/2006/index.jsp. For more information about the BIO CEO & Investor Conference, visit www.ceo.bio.org. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. BioSante also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com.